Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 April 2021Website:
http://werewolftx.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 6 min agoDividend
Analysts recommendations
Institutional Ownership
HOWL Latest News
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.
– Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting –
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 -
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers -
There is increasing optimism about the earnings potential of Werewolf Therapeutics (HOWL), leading to its upgrade to a Zacks Rank #2 (Buy) and a potential increase in stock price.
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.
Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of IL-2 selectively near the tumor, minimizing toxicity. Early data from phase 1 trials showed remarkable tolerability and PK/PD, as well as the faintest signals of efficacy.
Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company treating patients with advanced or metastatic solid tumors with its interleukin 2 INDUKINE molecule.
Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023. Another INDUKINE molecule being developed in the pipeline would be WTX-330, which is being advanced in a phase 1 open-label study treating patients with metastatic solid tumors and non-Hodgkin lymphoma. Werewolf has a collaboration agreement with Jazz Pharmaceuticals for the development of JZP898, an interferon alpha INDUKINE molecule, with potential milestone payments of up to $1.26 billion.
What type of business is Werewolf Therapeutics?
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
What sector is Werewolf Therapeutics in?
Werewolf Therapeutics is in the Healthcare sector
What industry is Werewolf Therapeutics in?
Werewolf Therapeutics is in the Biotechnology industry
What country is Werewolf Therapeutics from?
Werewolf Therapeutics is headquartered in United States
When did Werewolf Therapeutics go public?
Werewolf Therapeutics initial public offering (IPO) was on 30 April 2021
What is Werewolf Therapeutics website?
https://werewolftx.com
Is Werewolf Therapeutics in the S&P 500?
No, Werewolf Therapeutics is not included in the S&P 500 index
Is Werewolf Therapeutics in the NASDAQ 100?
No, Werewolf Therapeutics is not included in the NASDAQ 100 index
Is Werewolf Therapeutics in the Dow Jones?
No, Werewolf Therapeutics is not included in the Dow Jones index
When was Werewolf Therapeutics the previous earnings report?
No data
When does Werewolf Therapeutics earnings report?
The next expected earnings date for Werewolf Therapeutics is 14 November 2024